Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Antipsychotic Drugs Companies

ID: MRFR/Pharma/2067-HCR
90 Pages
Satyendra Maurya
Last Updated: February 16, 2025
Antipsychotic drugs, also known as neuroleptics, are a class of medications primarily used to manage symptoms of psychosis, including schizophrenia, bipolar disorder, and other mental health conditions. These drugs work by modulating the effects of neurotransmitters in the brain, particularly dopamine, which is believed to play a significant role in the development of psychotic symptoms.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Antipsychotic Drugs Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)7.64%
2024 Market Size$ 17.49 Billion
2025 Market Size$ 18.83 Billion
2035 Market Size$ 39.32 Billion

Key Players

Companies such as Johnson & Johnson
Pfizer
Roche
Eli Lilly and Company
AstraZeneca
Bristol-Myers Squibb
Opportunities
  • Regulatory Support and Approval
  • Innovations in Drug Formulations
  • Growing Prevalence of Mental Disorders

Top Industry Leaders in the Antipsychotic Drugs Market

Antipsychotic Drugs Key Companies
ย 

Latest Antipsychotic Drugs Companies Update

Intra-Cellular Therapies Received FDA approval for Caplyta (lumateperone) as adjunctive therapy for depressive episodes associated with bipolar I or II disorder, expanding its market reach.

Alkermes Announced positive results from ENLIGHTEN-early, a Phase 3b study evaluating LYBALVI for schizophrenia, providing further evidence for its efficacy and tolerability.

Luye Pharma Group Secured FDA approval for Rykindo for the treatment of schizophrenia and bipolar 1 disorder, offering a new option with a once-daily dosing schedule.

Otsuka Pharmaceutical Co., Ltd. and Lundbeck Received FDA approval for Rexulti (brexpiprazole) for the treatment of schizophrenia in adolescents (13-17 years old), addressing a crucial need in this underserved population.

List of Antipsychotic Drugs Key Companies in the Market

  • Johnson and Johnson (U.S.)

  • GlaxoSmithKline Plc. (U.K.)

  • Pfizer Inc. (U.S.)

  • AstraZeneca (U.K.)

  • Bristol-Myers Squibb (U.S.)

  • Eli Lily & Co. (U.S.)